PortfoliosLab logoPortfoliosLab logo
ARKG vs. SBIO
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

ARKG vs. SBIO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ARK Genomic Revolution Multi-Sector ETF (ARKG) and ALPS Medical Breakthroughs ETF (SBIO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ARKG achieves a 25.20% return, which is significantly higher than SBIO's 1.95% return. Both investments have delivered pretty close results over the past 10 years, with ARKG having a 7.74% annualized return and SBIO not far ahead at 8.03%.


ARKG

1D
6.93%
1M
21.79%
YTD
25.20%
6M
13.70%
1Y
60.42%
3Y*
2.68%
5Y*
-14.59%
10Y*
7.74%

SBIO

1D
2.35%
1M
-5.55%
YTD
1.95%
6M
4.13%
1Y
68.86%
3Y*
18.38%
5Y*
3.16%
10Y*
8.03%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ARKG vs. SBIO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF
25.20%23.04%-28.24%16.22%-53.90%-33.92%180.40%44.00%-1.26%46.61%
SBIO
ALPS Medical Breakthroughs ETF
1.95%55.07%3.81%8.68%-28.08%-17.55%21.17%50.30%-11.81%45.67%

Correlation

The correlation between ARKG and SBIO is 0.62, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.62

Correlation (3Y)
Calculated over the trailing 3-year period

0.72

Correlation (5Y)
Calculated over the trailing 5-year period

0.78

Correlation (10Y)
Calculated over the trailing 10-year period

0.78

Correlation (All Time)
Calculated using the full available price history since Jan 2, 2015

0.78

The correlation between ARKG and SBIO shifts across timeframes, from 0.62 (1 year) to 0.78 (10 years), reflecting how their relationship changes across market environments.

ARKG vs. SBIO - Sectors Allocation Comparison


Sectors
ARKG
SBIO

Healthcare

99.2%
100.0%

Financial Services

0.5%
-0.0%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

ARKG
99.2%
SBIO
100.0%

Financial Services

ARKG
0.5%
SBIO
-0.0%

Basic Materials

ARKG

-

SBIO

-

Communication Services

ARKG

-

SBIO

-

Consumer Cyclical

ARKG

-

SBIO

-

Consumer Defensive

ARKG

-

SBIO

-

Energy

ARKG

-

SBIO

-

Industrials

ARKG

-

SBIO

-

Real Estate

ARKG

-

SBIO

-

Technology

ARKG

-

SBIO

-

Utilities

ARKG

-

SBIO

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ARKG vs. SBIO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARKG
ARKG Risk / Return Rank: 4141
Overall Rank
ARKG Sharpe Ratio Rank: 4242
Sharpe Ratio Rank
ARKG Sortino Ratio Rank: 4444
Sortino Ratio Rank
ARKG Omega Ratio Rank: 3838
Omega Ratio Rank
ARKG Calmar Ratio Rank: 4646
Calmar Ratio Rank
ARKG Martin Ratio Rank: 3636
Martin Ratio Rank

SBIO
SBIO Risk / Return Rank: 7676
Overall Rank
SBIO Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
SBIO Sortino Ratio Rank: 7272
Sortino Ratio Rank
SBIO Omega Ratio Rank: 6363
Omega Ratio Rank
SBIO Calmar Ratio Rank: 9090
Calmar Ratio Rank
SBIO Martin Ratio Rank: 8282
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARKG vs. SBIO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ARKGSBIODifference
Sharpe ratioReturn per unit of total volatility

-0.89

Sortino ratioReturn per unit of downside risk

-1.05

Omega ratioGain probability vs. loss probability

1.24

1.38

-0.13

Calmar ratioReturn relative to maximum drawdown

2.21

5.47

-3.26

Martin ratioReturn relative to average drawdown

5.29

16.23

-10.94

ARKG vs. SBIO - Sharpe Ratio Comparison

The current ARKG Sharpe Ratio is 1.46, which is lower than the SBIO Sharpe Ratio of 2.35. The chart below compares the historical Sharpe Ratios of ARKG and SBIO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ARKGSBIODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.46

2.35

-0.89

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.32

0.09

-0.42

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.19

0.24

-0.05

Sharpe Ratio (All Time)

Calculated using the full available price history

0.15

0.22

-0.07

Drawdowns

ARKG vs. SBIO - Drawdown Comparison

The maximum ARKG drawdown since its inception was -83.59%, which is greater than SBIO's maximum drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for ARKG and SBIO.


Loading charts...

Drawdown Indicators


ARKGSBIODifference

Max Drawdown

Largest peak-to-trough decline

-83.59%

-63.06%

-20.53%

Max Drawdown (1Y)

Largest decline over 1 year

-27.51%

-12.66%

-14.85%

Max Drawdown (3Y)

Largest decline over 3 years

-51.96%

-42.44%

-9.52%

Max Drawdown (5Y)

Largest decline over 5 years

-80.18%

-53.10%

-27.08%

Max Drawdown (10Y)

Largest decline over 10 years

-83.59%

-63.06%

-20.53%

Current Drawdown

Current decline from peak

-67.55%

-14.84%

-52.71%

Average Drawdown

Average peak-to-trough decline

-35.88%

-28.44%

-7.44%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.46%

4.26%

+7.20%

Volatility

ARKG vs. SBIO - Volatility Comparison

ARK Genomic Revolution Multi-Sector ETF (ARKG) has a higher volatility of 12.94% compared to ALPS Medical Breakthroughs ETF (SBIO) at 9.85%. This indicates that ARKG's price experiences larger fluctuations and is considered to be riskier than SBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ARKGSBIODifference

Volatility (1M)

Calculated over the trailing 1-month period

12.94%

9.85%

+3.09%

Volatility (6M)

Calculated over the trailing 6-month period

29.51%

22.76%

+6.75%

Volatility (1Y)

Calculated over the trailing 1-year period

41.62%

29.40%

+12.22%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

45.71%

33.57%

+12.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

41.17%

33.18%

+7.99%

ARKG vs. SBIO - Expense Ratio Comparison

ARKG has a 0.75% expense ratio, which is higher than SBIO's 0.50% expense ratio.


Dividends

ARKG vs. SBIO - Dividend Comparison

Neither ARKG nor SBIO has paid dividends to shareholders.


PositionTTM202520242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF
0.00%0.00%0.00%0.00%0.00%0.62%0.85%3.14%0.82%1.34%
SBIO
ALPS Medical Breakthroughs ETF
0.00%0.00%3.55%0.22%0.00%0.00%0.00%0.04%2.79%1.77%

Frequently Asked Questions


ARKG and SBIO have a correlation of 0.62, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ARKG has higher volatility (12.94%) compared to SBIO (9.85%). In terms of maximum drawdown, ARKG dropped -83.59% vs SBIO's -63.06%.

On 10-year performance, SBIO leads with 8.03% vs 7.74% for ARKG. On fees, SBIO is cheaper at 0.50% per year. On volatility, SBIO has been the lower-risk option at 9.85%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, SBIO has performed better with a 8.03% return vs 7.74%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

SBIO is cheaper with a 0.50% expense ratio, compared with 0.75% for ARKG.

ARKG and SBIO have nearly identical dividend yields, around 0.00%.

They also come from different issuers: ARK and SS&C. Their fees differ too: 0.75% for ARKG and 0.50% for SBIO.

SBIO currently has the higher Sharpe Ratio (2.35 vs 1.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ARKG and SBIO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer